Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension.

ABSTRACT:

Background

Fibroblast growth factor 23 (FGF-23) has been associated with left ventricular hypertrophy (LVH) and heart failure. However, its role in right ventricular (RV) remodeling and RV failure is unknown. This study analyzed the utility of FGF-23 as a biomarker of RV function in patients with pulmonary hypertension (PH).

Methods

In this observational study, FGF-23 was measured in the plasma of patients with PH (n = 627), dilated cardiomyopathy (DCM, n = 59), or LVH with severe aortic stenosis (n = 35). Participants without LV or RV abnormalities served as controls (n = 36).

Results

Median FGF-23 plasma levels were higher in PH patients than in healthy controls (p < 0.001). There were no significant differences between PH, DCM, and LVH patients. Analysis across ter

SUBMITTER: Widmann L 

PROVIDER: S-EPMC10562503 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature